Qiagen NV (Qiagen NV) Cash, Cash Equivalents, Marketable Securities

: $1,058 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Qiagen NV's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($1,331.90 Mil) to Sep. 2023 ($1,015.78 Mil) but then increased from Sep. 2023 ($1,015.78 Mil) to Dec. 2023 ($1,057.78 Mil).

Qiagen NV's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($1,065.30 Mil) to Dec. 2022 ($1,418.27 Mil) but then declined from Dec. 2022 ($1,418.27 Mil) to Dec. 2023 ($1,057.78 Mil).

Qiagen NV Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Qiagen NV's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

753.23

715.23

1,065.30

1,418.27

1,057.78

Qiagen NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities																1,418.27	1,287.34	1,331.90	1,015.78	1,057.78

Qiagen NV Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Qiagen NV (NYSE:QGEN) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Qiagen NV Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Qiagen NV (Qiagen NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

1QGEN:Italy QIAd:UK 0RLT:UK QIA:Germany QIA:Germany QIA:Germany QIA:Germany QGEN:Austria

Address

Hulsterweg 82, Venlo, LI, NLD, 5912 PL

Website

https://www.qiagen.com

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Executives